Congress Materials – Association of Pulmonary Advanced Practice Providers (APAPP 2025)
2025 Association of Pulmonary Advanced Practice Providers | Jun 26-28 | Nashville, TN
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
10-year data on oral selexipag: long-term survival, safety, and dosing insights in pulmonary arterial hypertension (PAH) from the GRIPHON study and its open-label extension (OLE)
Vallerie V. McLaughlin, Luke Howard, Jean Elwing, Catarina C Fernandes, Sean Gaine, Nazzareno Galiè, Nicolas Martin, Ronald J Oudiz, Paul Strachan, Yuichi Tamura, Nick H. Kim
Delphi study investigating the clinical use of oral selexipag to treat pulmonary arterial hypertension (PAH)
Wu S, Doad G, Benninger C, Cho M, Perry R, Bridge D, Oswald C, Val-Maranes L, Strachan P
Expert consensus on the definition of methamphetamine- associated pulmonary arterial hypertension (Meth-APAH) and associated treatment considerations
Zamanian R, Leary P, Sargent T, Kingrey J, Lopez D, Adhia A, Doad G, Stone M, Bridge D, Perry R, Enstone A, Perrett L, Smith H, Sandros M, Kim NH
Methamphetamine-Associated Pulmonary Arterial Hypertension: Uncovering an urgent unmet medical need in the US via analytics and insights
Vinicio de Jesus Perez, John Kingrey, W. David Hardy, Gan Tan, Ankita Adhia, David Lopez, Michelle Cho, Marinella Sandros, John J. Ryan
Patient preferences regarding the use of combination ERA+PDE5i for the treatment of pulmonary arterial hypertension: Results from a discrete choice experiment
M. Wilson, M. Kingman, N.A. Kolaitis, L. Melendres-Groves, G.G. Rendon, C.J. Paoli, D. Lopez, M. Rahman, A. Martin, S. Mirza, N. McGarvey, A. Lee
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.